AI tools promise that anyone can build apps, so I put that claim to the test. After a few minor bumps, I built a custom ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Flight cuts to hit 40 busiest U.S. airports due to government shutdown, computer chips in our bodies could be the future of medicine, and more Length: Long Speed: 1.0x It's been a long time since ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...